Cheng Xin / Getty Photographs
Shares of DexCom (DXCM) jumped greater than 15% to tempo the S&P 500‘s advancers Friday, a day after the maker of glucose monitoring units for individuals with diabetes reported better-than-expected quarterly income and introduced a $750 million stock buyback program.
After the closing bell Thursday, San Diego-based DexCom reported first-quarter income that grew 12% year-over-year to $1.04 billion. Analysts surveyed by Seen Alpha anticipated $1.02 billion. Adjusted earnings per share of 32 cents missed estimates by a penny.
DexCom affirmed its full-year outlook for income of $4.6 billion, adjusted operating margin of roughly 21%, and adjusted EBITDA margin of about 30%.
Nonetheless, it lowered its 2025 projection for adjusted gross profit margin to roughly 62% due to “incremental prices associated to near-term provide dynamics.”
Friday’s surge moved shares of DexCom into constructive territory for 2025. At round $81, they’re nonetheless a bit off Seen Alpha’s common analyst worth goal, which is presently a bit above $98.
Learn the unique article on Investopedia
